GO:0032740 positive regulation of interleukin-17 production: Immune Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032740 describes any process that activates or increases the frequency, rate, or extent of production of interleukin-17 family cytokines.
• IL-17 cytokines are produced mainly by CD4+ Th17 cells, gamma-delta T cells, ILC3s, and other innate-like lymphocytes.
• Positive regulation of IL-17 production is driven by cytokines such as IL-6, IL-23, IL-1beta, and TGF-beta, and by transcription factors including RORgamma-t and STAT3.
• IL-17-producing cells are central to mucosal immunity but also drive pathology in autoimmunity, colitis, and cancer.
• Blocking IL-17A can enhance tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
• CRISPR knockout, knock-in, and overexpression models are essential to dissect causal regulators of IL-17 production.
Description
GO:0032740, positive regulation of interleukin-17 production, is a biological process term in the Gene Ontology that captures any mechanism that activates or increases the frequency, rate, or extent of production of interleukin-17 family cytokines. Interleukin-17 (IL-17) cytokines are key effector molecules of mucosal immunity, produced predominantly by CD4+ Th17 cells, gamma-delta T cells, innate lymphoid cells (ILC3s), and other innate-like lymphocytes. The regulation of IL-17 production is critical for host defense against extracellular bacteria and fungi, but dysregulated IL-17 responses contribute to autoimmune and inflammatory diseases. Understanding the positive regulation of IL-17 production is therefore essential for immunology researchers, drug developers, and clinicians targeting IL-17 pathways. This article provides a research-grade overview of GO:0032740, integrating authoritative QuickGO annotation data with real PubMed literature to describe its definition, mechanisms, key genes, disease relevance, and experimental models.
positive regulation of interleukin-17 production At A Glance
| GO ID | GO:0032740 |
|---|---|
| GO term | positive regulation of interleukin-17 production |
| Ontology | biological_process |
| Synonym | activation of interleukin-17 production; positive regulation of IL-17 production; positive regulation of interleukin-17 secretion; upregulation of interleukin-17 production |
| Major function | Increases the frequency, rate, or extent of production of IL-17 family cytokines |
| Cellular context | CD4+ Th17 cells, gamma-delta T cells, ILC3s, innate-like lymphocytes, and other IL-17-producing cells |
| Key regulators | IL-6, IL-23, IL-1beta, TGF-beta, RORgamma-t, STAT3, NRP1 |
| Disease relevance | Autoimmunity, inflammatory bowel disease, colorectal cancer, neuroinflammation |
What Is GO:0032740?
According to the Gene Ontology, GO:0032740 (positive regulation of interleukin-17 production) is defined as any process that activates or increases the frequency, rate, or extent of production of any member of the interleukin-17 family of cytokines. This includes transcriptional activation, post-transcriptional stabilization, and secretion of IL-17 proteins. The term is a child of positive regulation of cytokine production and encompasses synonyms such as activation of interleukin-17 production, positive regulation of IL-17 production, and positive regulation of interleukin-17 secretion.
Why Is positive regulation of interleukin-17 production Important in Cell Biology?
Positive regulation of interleukin-17 production is a central node in immune signaling because IL-17 cytokines orchestrate neutrophil recruitment, antimicrobial peptide production, and mucosal barrier maintenance. Dysregulated IL-17 production is implicated in the pathogenesis of autoimmune diseases such as psoriasis, rheumatoid arthritis, and multiple sclerosis, as well as inflammatory bowel diseases. In cancer, IL-17 can promote tumorigenesis or antitumor immunity depending on context, and blocking IL-17A has been shown to enhance tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. Understanding the positive regulation of IL-17 production is therefore critical for developing targeted therapies that modulate IL-17 responses without compromising host defense.
• IL-17 cytokines are essential for host defense against extracellular bacteria and fungi at mucosal surfaces.
• Dysregulated IL-17 production drives autoimmune and inflammatory diseases including psoriasis, rheumatoid arthritis, and colitis.
• IL-17-producing ILC3s instructed by NRP1 drive colitis progression, highlighting cell-specific regulation.
• Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
• IL-17A-mediated mitochondrial dysfunction induces pyroptosis in colorectal cancer cells and promotes CD8+ T-cell tumor infiltration.
• The gut microbiome controls reactive astrocytosis during Aβ amyloidosis via propionate-mediated regulation of IL-17.
• IL-17 production is regulated by cytokines (IL-6, IL-23, IL-1beta, TGF-beta) and transcription factors (RORgamma-t, STAT3).
• Measurement of IL-17 is a standard immunological assay for Th17 responses.
• IL-17A is a validated drug target, with anti-IL-17 biologics approved for psoriasis and other inflammatory diseases.
• CRISPR-based models enable causal dissection of genes that positively regulate IL-17 production.
What Happens During positive regulation of interleukin-17 production?
Initiation by Cytokine Signals
In simple terms: Cytokines tell immune cells to start making IL-17.
Positive regulation of IL-17 production is initiated when naive CD4+ T cells or innate lymphoid cells receive cytokine signals, typically IL-6, IL-1beta, IL-23, and TGF-beta, which activate downstream transcription factors such as STAT3 and RORgamma-t. These signals promote the differentiation and activation of Th17 cells and ILC3s, leading to transcriptional activation of IL17A, IL17F, and related genes.
Transcriptional Activation of IL-17 Genes
In simple terms: Master transcription factors switch on the IL-17 genes.
The transcription factor RORgamma-t (RORC) is a master regulator of IL-17 production, binding to regulatory elements in the IL17A and IL17F loci and cooperating with STAT3, BATF, and IRF4 to drive transcription. Positive regulation of IL-17 production therefore involves chromatin remodeling and recruitment of transcriptional coactivators at these loci.
Post-Transcriptional and Secretory Control
In simple terms: Cells also control how much IL-17 protein is made and released.
Beyond transcription, positive regulation of IL-17 production includes mRNA stabilization and efficient secretion of IL-17 proteins. Cytokines such as IL-23 can enhance IL-17 secretion from already differentiated Th17 cells, and measurement of secreted IL-17 is a standard readout of this process.
Amplification by Innate and Microenvironmental Cues
In simple terms: Other cells and signals can boost IL-17 production further.
Innate lymphoid cells (ILC3s) and gamma-delta T cells can rapidly produce IL-17 in response to microbial and inflammatory cues, amplifying the response. NRP1 has been shown to instruct IL-17-producing ILC3s to drive colitis progression, illustrating how microenvironmental factors positively regulate IL-17 production. The gut microbiome can also modulate IL-17 production via metabolites such as propionate.
Key Genes Involved in GO:0032740 positive regulation of interleukin-17 production
The following genes and proteins are central to the positive regulation of interleukin-17 production, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL17A | Encodes IL-17A cytokine, the principal effector of the IL-17 family | Primary readout for GO:0032740; target of anti-IL-17 therapies |
| IL17F | Encodes IL-17F cytokine, co-expressed with IL-17A in Th17 cells | Marker of Th17 responses; contributes to mucosal immunity |
| RORC | Encodes RORgamma-t, master transcription factor for Th17 differentiation and IL-17 production | Key positive regulator; knockout abolishes IL-17 production |
| STAT3 | Signal transducer and activator of transcription 3; mediates IL-6 and IL-23 signaling | Essential for Th17 differentiation and IL-17 production |
| IL6 | Pro-inflammatory cytokine that promotes Th17 differentiation | Induces positive regulation of IL-17 production |
| IL23A | Subunit of IL-23, which stabilizes and expands Th17 cells | Critical for sustained IL-17 production |
| IL1B | Pro-inflammatory cytokine that enhances Th17 responses | Synergizes with IL-6 and IL-23 to boost IL-17 |
| TGFB1 | Cytokine that promotes Th17 differentiation in combination with IL-6 | Context-dependent positive regulator |
| NRP1 | Neuropilin-1; instructs IL-17-producing ILC3s | Drives colitis progression via ILC3-derived IL-17 |
| BATF | Transcription factor cooperating with RORgamma-t | Enhances IL-17 gene transcription |
| IRF4 | Interferon regulatory factor 4; supports Th17 differentiation | Contributes to positive regulation of IL-17 |
| AHR | Aryl hydrocarbon receptor; senses environmental ligands | Promotes Th17 differentiation and IL-17 production |
| IL17RA | Receptor for IL-17A and IL-17F | Mediates downstream signaling of IL-17 |
| TNF | Pro-inflammatory cytokine that can amplify IL-17 responses | Synergizes with IL-17 in inflammation |
| CXCL1 | Chemokine induced by IL-17; recruits neutrophils | Downstream effector of IL-17 signaling |
| DEFB4 | Beta-defensin 4; antimicrobial peptide induced by IL-17 | Readout of IL-17 activity |
| MMP3 | Matrix metalloproteinase 3; induced by IL-17 | Tissue remodeling effector |
| FOXP3 | Regulatory T cell transcription factor; can suppress IL-17 production | Negative regulator counterbalancing positive regulation |
How Is positive regulation of interleukin-17 production Regulated?
Positive regulation of IL-17 production is controlled by a network of cytokines, transcription factors, and environmental cues. IL-6 and TGF-beta initiate Th17 differentiation, while IL-23 sustains IL-17 production and effector function. STAT3 and RORgamma-t are central transcriptional regulators, and BATF and IRF4 cooperate to enhance IL17A transcription. Negative regulators such as FOXP3 and regulatory T cells counterbalance these positive signals. In innate lymphoid cells, NRP1 instructs IL-17-producing ILC3s to drive colitis progression. The gut microbiome can modulate IL-17 production via metabolites such as propionate, which affects reactive astrocytosis during Aβ amyloidosis. These layers of regulation ensure that IL-17 production is tightly controlled in health and disease.
positive regulation of interleukin-17 production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL17A | Psoriasis, rheumatoid arthritis, colorectal cancer | IL17A knockout mouse; anti-IL-17A antibody treatment in tumor models |
| RORC | Autoimmunity, Th17-mediated inflammation | RORC knockout or point-mutation cell models |
| NRP1 | Colitis progression | NRP1 knockout ILC3 models; colitis mouse models |
| IL23A | Inflammatory bowel disease, psoriasis | IL23A knockout mice; IL-23 blockade |
| STAT3 | Autoimmunity, cancer | STAT3 knockout or knock-in cell lines |
Autoimmune and Inflammatory Diseases
Dysregulated positive regulation of IL-17 production is a hallmark of autoimmune and inflammatory diseases such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease. IL-17-producing ILC3s instructed by NRP1 drive colitis progression, demonstrating a direct link between IL-17 regulation and intestinal inflammation. Anti-IL-17 biologics have proven effective in psoriasis, validating the pathway as a therapeutic target.
Colorectal Cancer
In microsatellite stable colorectal cancer, blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy, indicating that IL-17 production can promote immune evasion. IL-17A-mediated mitochondrial dysfunction induces pyroptosis in colorectal cancer cells and promotes CD8+ T-cell tumor infiltration, revealing complex roles for IL-17 in tumor immunity. These findings highlight the importance of context in targeting IL-17 production for cancer therapy.
Neuroinflammation and Neurodegeneration
The gut microbiome controls reactive astrocytosis during Aβ amyloidosis via propionate-mediated regulation of IL-17, linking IL-17 production to Alzheimer's disease pathology. This suggests that modulating IL-17 production may influence neuroinflammatory processes in neurodegeneration.
From positive regulation of interleukin-17 production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X positively regulate IL-17 production? | CRISPR knockout in Th17 or ILC3 cells followed by IL-17 ELISA |
| Does a specific point mutation in RORC alter IL-17 production? | CRISPR point-mutation knock-in in T cell lines |
| Does overexpression of NRP1 enhance IL-17 production in ILC3s? | CRISPR overexpression or lentiviral overexpression in ILC3 cells |
| Does a tagged allele of IL17A report production dynamics? | CRISPR knock-in of fluorescent or epitope tag at IL17A locus |
| Does microbiome-derived propionate regulate IL-17 in vivo? | Germ-free or antibiotic-treated mouse models with propionate supplementation |
| Does IL-17A blockade improve immunotherapy response? | Syngeneic colorectal cancer mouse models treated with anti-PD-1 and anti-IL-17A |
How to Study the positive regulation of interleukin-17 production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ELISA | Secreted IL-17A/F protein levels | Quantifying positive regulation of IL-17 production in cell culture |
| ELISPOT | Frequency of IL-17-secreting cells | Detecting antigen-specific Th17 responses |
| Flow cytometry | Intracellular IL-17 and surface markers | Phenotyping Th17 and ILC3 cells |
| RNA-seq | Transcript levels of IL17A, IL17F, and related genes | Assessing transcriptional regulation |
| ATAC-seq | Chromatin accessibility at IL-17 loci | Identifying regulatory elements |
| ChIP-seq | Binding of RORgamma-t, STAT3, BATF at target genes | Mapping direct regulators |
| CRISPR knockout screen | Gene requirements for IL-17 production | Unbiased discovery of positive regulators |
| Multiplex cytokine profiling | Panel of cytokines including IL-17 | Characterizing immune cell activation states |
Cytokine Quantification Assays
Measurement of IL-17 production is typically performed using ELISA, ELISPOT, or intracellular cytokine staining followed by flow cytometry. These methods quantify secreted or intracellular IL-17A and IL-17F and are standard readouts for positive regulation of IL-17 production.
Transcriptional and Epigenetic Profiling
RNA-seq and ATAC-seq can be used to assess transcriptional activation of IL17A and IL17F and chromatin accessibility at these loci. ChIP-seq for RORgamma-t and STAT3 can identify direct binding events that drive positive regulation of IL-17 production.
CRISPR Screening and Functional Genomics
Pooled CRISPR knockout screens in Th17 or ILC3 cells can identify genes that positively or negatively regulate IL-17 production. Such screens enable unbiased discovery of regulators and are complemented by bioinformatics analysis.
In Vivo Models of Inflammation and Cancer
Mouse models of colitis, autoimmunity, and cancer are used to study the role of IL-17 production in disease. For example, anti-IL-17A treatment in colorectal cancer models enhances anti-PD-1 responses, and NRP1-deficient ILC3s reduce colitis progression.
How CRISPR Can Be Used to Study GO:0032740 positive regulation of interleukin-17 production
Knockout
CRISPR knockout of candidate genes such as RORC, STAT3, or NRP1 in Th17 or ILC3 cells can determine whether they are required for positive regulation of IL-17 production. Knockout models are validated by IL-17 ELISA and flow cytometry.
Point Mutation
CRISPR point mutation can introduce specific amino acid changes in transcription factors like RORgamma-t to dissect domains required for IL-17 gene activation. Such models help distinguish DNA-binding versus coactivator functions.
Knock-in
Knock-in of fluorescent reporters (e.g., GFP) at the IL17A locus enables real-time tracking of IL-17-producing cells. Tagged knock-in of IL-17A allows purification and biochemical analysis of secreted cytokine.
Overexpression
CRISPR-mediated overexpression or lentiviral overexpression of genes such as NRP1 or IL23R can test sufficiency for enhancing IL-17 production. Overexpression models are useful for gain-of-function studies in primary or immortalized immune cells.
How EDITGENE Supports positive regulation of interleukin-17 production Research
Researchers studying positive regulation of interleukin-17 production-related genes often need to determine whether a candidate gene is causally involved in driving IL-17 cytokine production. EDITGENE provides a comprehensive suite of CRISPR-based cell model services to enable such causal studies, from knockout to knock-in and overexpression, supported by library screening and bioinformatics.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of interleukin-17 production research.
Frequently Asked Questions About positive regulation of interleukin-17 production
What is GO:0032740?
GO:0032740 is the Gene Ontology term for positive regulation of interleukin-17 production, defined as any process that activates or increases the frequency, rate, or extent of production of IL-17 family cytokines.
What genes are involved in positive regulation of interleukin-17 production?
Key genes include IL17A, IL17F, RORC, STAT3, IL6, IL23A, IL1B, TGFB1, NRP1, BATF, IRF4, and AHR.
Which cells produce interleukin-17?
IL-17 is produced mainly by CD4+ Th17 cells, gamma-delta T cells, ILC3s, and other innate-like lymphocytes.
How is IL-17 production measured?
IL-17 production is commonly measured by ELISA, ELISPOT, or intracellular cytokine staining followed by flow cytometry.
What diseases are linked to IL-17 production?
IL-17 production is linked to psoriasis, rheumatoid arthritis, inflammatory bowel disease, colitis, colorectal cancer, and neuroinflammation.
Can CRISPR be used to study IL-17 regulation?
Yes, CRISPR knockout, knock-in, point mutation, and overexpression models are widely used to dissect regulators of IL-17 production.
What is the role of RORgamma-t in IL-17 production?
RORgamma-t (encoded by RORC) is a master transcription factor that drives IL17A and IL17F transcription and is essential for Th17 differentiation.
How does the gut microbiome affect IL-17 production?
The gut microbiome can modulate IL-17 production via metabolites such as propionate, which affects reactive astrocytosis during Aβ amyloidosis.
Does blocking IL-17 improve cancer immunotherapy?
In microsatellite stable colorectal cancer, blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy.
What is the difference between IL-17A and IL-17F?
IL-17A and IL-17F are related cytokines encoded by distinct genes, both produced by Th17 cells and sharing the IL-17RA receptor, but with different potency and tissue distribution.
Conclusion
GO:0032740, positive regulation of interleukin-17 production, is a critical biological process that governs the generation of IL-17 family cytokines by Th17 cells, ILC3s, and other immune cells. Its dysregulation contributes to autoimmune diseases, inflammatory bowel disease, cancer, and neuroinflammation, making it a high-value target for therapeutic intervention. Advances in CRISPR-based cell modeling and functional genomics now allow researchers to systematically dissect the positive regulators of IL-17 production and translate these insights into new treatments.
References
- 1. Mills KHG. 2023. IL-17 and IL-17-producing cells in protection versus pathology.. Nat Rev Immunol 23(1):38-54 PMID: 35790881
- 2. Liu C et al.. 2021. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.. J Immunother Cancer 9(1) PMID: 33462141
- 3. Wang Y et al.. 2025. NRP1 instructs IL-17-producing ILC3s to drive colitis progression.. Cell Mol Immunol 22(2):161-175 PMID: 39741194
- 4. Chen K et al.. 2017. Interluekin-17A (IL17A).. Gene 614:8-14 PMID: 28122268
- 5. Chandra S et al.. 2025. The gut microbiome controls reactive astrocytosis during Aβ amyloidosis via propionate-mediated regulation of IL-17.. J Clin Invest 135(13) PMID: 40359034
- 6. Pappu BP et al.. 2007. Measurement of interleukin-17.. Curr Protoc Immunol Chapter 6:6.25.1-6.25.8 PMID: 18432994
- 7. Feng WQ et al.. 2023. IL-17A-mediated mitochondrial dysfunction induces pyroptosis in colorectal cancer cells and promotes CD8 + T-cell tumour infiltration.. J Transl Med 21(1):335 PMID: 37211606
- 8. Chen Z et al.. 2008. Regulation of IL-17 production in human lymphocytes.. Cytokine 41(2):71-8 PMID: 17981475
